BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BMS-986548 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BMS-986548\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07939815-11191@assetmemo.bio
DTSTAMP:20261121T005557Z
DTSTART;VALUE=DATE:20291229
DTEND;VALUE=DATE:20291230
SUMMARY:BMS-986548: Phase 1/2 readout est. (NCT07939815)
DESCRIPTION:BMS-986548\, phase 1/2.\nStudy: A Study of BMS-986548 as Monoth
 erapy and in Combination With Anti-cancer Agents in Participants With Adva
 nced Solid Malignancies\nEstimated primary completion: 29 December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bms-986548#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07939815
URL:https://assetmemo.bio/drug/bms-986548#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
